Haptoglobin genotype and renal function decline in type 1 diabetes

Diabetes

Volumn 58, Issue 12, 2009, Pages 2904-2909

  Costacou, Tina ^a   Ferrell, Robert E ^b   Ellis, Demetrius ^c   Orchard, Trevor J ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HAPTOGLOBIN;

ADOLESCENT; ADULT; ALBUMINURIA; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK; SYSTOLIC BLOOD PRESSURE;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; ALBUMINURIA; DIABETES MELLITUS, TYPE 1; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GENOTYPE; GLOMERULAR FILTRATION RATE; HAPTOGLOBINS; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ODDS RATIO; OXIDATIVE STRESS; PENNSYLVANIA; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; YOUNG ADULT;

EID: 73249149340     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-0874     Document Type: Article

References (35)

1. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999;48:1-9
2. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, Gerstein HC, HOPE Study, MICRO-HOPE Study. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 2002;25:1919-1927
3. Levy AP. Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy. Pharmacol Ther 2006;112:501-512
4. Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem 1996;42:1589-1600
5. Kristiansen M, Graversen JH, Jacobsen C, Sonne O, Hoffman HJ, Law SK, Moestrup SK. Identification of the haemoglobin scavenger receptor. Nature 2001;409:198-201
6. Asleh R, Levy AP. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease. Vasc Health Risk Manag 2005;1:19-28
7. Asleh R, Marsh S, Shilkrut M, Binah O, Guetta J, Lejbkowicz F, Enav B, Shehadeh N, Kanter Y, Lache O, Cohen O, Levy NS, Levy AP. Genetically determined heterogeneity in Hb scavenging and susceptibility to diabetic cardiovascular disease. Circ Res 2003;92:1193-1200
8. Asleh R, Guetta J, Kalet-Litman S, Miller-Lotan R, Levy AP. Haptoglobin genotype-and diabetes-dependent differences in iron-mediated oxidative stress in vitro and in vivo. Circ Res 2005;96:435-441
9. Levy AP, Purushothaman KR, Levy NS, Purushothaman M, Strauss M, Asleh R, Marsh S, Cohen O, Moestrup SK, Moller HJ, Zias EA, Benhayon D, Fuster V, Moreno PR. Downregulation of the Hb scavenger receptor in individuals with diabetes and the Hp 2-2 genotype: implications for the response to intraplaque hemorrhage and plaque vulnerability. Circ Res 2007;101:106-110
10. Asleh R, Miller-Lotan R, Aviram M, Hayek T, Yulish M, Levy JE, Miller B, Blum S, Milman U, Shapira C, Levy AP. Haptoglobin genotype is a regulator of reverse cholesterol transport in diabetes in vitro and in vivo. Circ Res 2006;99:1419-1425
11. Levy AP, Hochberg I, Jablonski K, Resnick HE, Lee ET, Best L, Howard BV, Strong Heart Study. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: the Strong Heart Study. J Am Coll Cardiol 2002;40:1984-1990
12. Suleiman M, Aronson D, Asleh R, Kapeliovich MR, Roguin A, Meisel SR, Shochat M, Sulieman A, Reisner SA, Markiewicz W, Hammerman H, Lotan R, Levy NS, Levy AP. Haptoglobin polymorphism predicts 30-day mortality and heart failure in patients with diabetes and acute myocardial infarction. Diabetes 2005;54:2802-2806
13. Levy AP, Gerstein H, Lotan R, Ratner R, McQueen M, Lonn E, Pogue J. The effect of vitamin E supplementation on cardiovascular risk in diabetic individuals with different haptoglobin phenotypes. Diabetes Care 2004;27:2767
14. Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, Alshiek J, Bennett L, Kostenko M, Landau M, Keidar S, Levy Y, Khemlin A, Radan A, Levy AP. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008;28:341-347
15. Costacou T, Ferrell RE, Orchard TJ. Haptoglobin genotype: a determinant of cardiovascular complication risk in type 1 diabetes. Diabetes 2008;57:1702-1706
16. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, LaPorte RE, Kuller LH. Prevalence of complications of IDDM by sex and duration: Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 1990;39:1116-1124
17. Wagener DK, Sacks JM, LaPorte RE, Macgregor JM. The Pittsburgh Study of insulin-dependent diabetes mellitus: risk for diabetes among relatives of IDDM. Diabetes 1982;31:136-144
18. Borhani NO, Kass EH, Langford HG, Payne GH, Remington RD, Stamler J, HDFP Cooperative Group. The hypertension detection and follow-up program. Prev Med 1976;5:207-215
19. Warnick GR, Albers JJ. Heparin-Mn2+ quantitation of high-density- lipoprotein cholesterol: an ultrafiltration procedure for lipemic samples. Clin Chem 1978;24:900-904
20. National Institutes of Health and Department of Health. Lipid Research Clinics Program. Washington, DC, US Government Printing Office, 1975
21. Allain CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem 1974;20:470-475
22. Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem 1973;19:476-482
23. Ellis D, Buffone GJ. A new approach to the evaluation of proteinuric states. Clin Chem 1977;23:666-670
24. Ellis D, Coonrod BA, Dorman JS, Kelsey SF, Becker DJ, Avner ED, Orchard TJ. Choice of urine sample predictive of microalbuminuria in patients with insulin-dependent diabetes mellitus. Am J Kidney Dis 1989;13:321-328
25. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
26. Koch W, Latz W, Eichinger M, Roguin A, Levy AP, Schömig A, Kastrati A. Genotyping of the common haptoglobin Hp 1/2 polymorphism based on PCR. Clin Chem 2002;48:1377-1382
27. Victor J, Cheong W, Chen JJS, Levy N, Miller-Lotan R, Levy AP, Blum S, Orchard TJ, Evans RW, Costacou T, Hauth BA. Clinical results of a rapid screening assay for haptoglobin 2-2: a cardiovascular disease risk marker in diabetes (Abstract). Diabetes 2009;58(Suppl. 1):A176
28. Levy AP, Roguin A, Hochberg I, Herer P, Marsh S, Nakhoul FM, Skorecki K. Haptoglobin phenotype and vascular complications in patients with diabetes. N Engl J Med 2000;343:969-970
29. Conway BR, Savage DA, Brady HR, Maxwell AP. Association between haptoglobin gene variants and diabetic nephropathy: haptoglobin polymorphism in nephropathy susceptibility. Nephron Exp Nephrol 2007;105:e75-e79
30. Koda Y, Soejima M, Yamagishi S, Amano S, Okamoto T, Inagaki Y, Yamada K, Kimura H. Haptoglobin genotype and diabetic microangiopathies in Japanese diabetic patients. Diabetologia 2002;45:1039-1040
31. Ellis D, Forrest KY, Erbey J, Orchard TJ. Urinary measurement of transforming growth factor-β and type IV collagen as new markers of renal injury: application in diabetic nephropathy. Clin Chem 1998;44:950-956
32. Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003;289:3273-3277
33. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006;55:1832-1839
34. Costacou T, Ellis D, Fried L, Orchard TJ. Sequence of progression of albuminuria and decreased GFR in persons with type 1 diabetes: a cohort study. Am J Kidney Dis 2007;50:721-732
35. Nakhoul FM, Miller-Lotan R, Awad H, Asleh R, Jad K, Nakhoul N, Asaf R, Abu-Saleh N, Levy AP. Pharmacogenomic effect of vitamin E on kidney structure and function in transgenic mice with the haptoglobin 2-2 genotype and diabetes mellitus. Am J Physiol Renal Physiol 2009;296:F830-F838